EE165 A Cost-Consequence Analysis of Ponatinib Versus Imatinib in Patients with Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.464
https://www.valueinhealthjournal.com/article/S1098-3015(24)00579-5/fulltext
Title :
EE165 A Cost-Consequence Analysis of Ponatinib Versus Imatinib in Patients with Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00579-5&doi=10.1016/j.jval.2024.03.464
First page :
Section Title :
Open access? :
No
Section Order :
11808